"Geron's Imetelstat Receives FDA Advisers' Backing for Blood Disorder Treatment"
TL;DR Summary
FDA advisers backed Geron's blood disorder drug, imetelstat, for treating transfusion-dependent anemia in patients with myelodysplastic syndromes, despite concerns about risks and toxicities. The panel voted 12-to-2 in favor of the drug's benefits, with discussions focusing on the high rate of cytopenias in patients tested with the drug. If approved, imetelstat will compete with Bristol Myers Squibb's Reblozyl and is projected to generate $933 million in sales by 2029. The FDA is expected to make a decision on the drug by June 16.
Topics:business#blood-disorder#fda#geron#health-pharmaceuticals#imetelstat#myelodysplastic-syndromes
- UPDATE 3-Geron's blood disorder drug gets FDA advisers' backing Yahoo Finance
- Geron's blood disorder drug gets FDA advisers' backing Yahoo! Voices
- Geron faces uphill battle at FDA meeting as agency questions benefit-risk profile of imetelstat Fierce Biotech
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS Business Wire
- Geron stock slips as FDA reviews blood cancer drug imetelstat Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
78%
382 → 83 words
Want the full story? Read the original article
Read on Yahoo Finance